ALBO / Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?

Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year. more_horizontal

Albireo Pharma, Inc. has entered into an agreement to get acquired by Ipsen. Bylvay is already approved for PFIC. Nevertheless, the stellar drug is po more_horizontal

Albireo promotes international sales of its approved product Bylvay for the treatment of the extremely rare and orphan disease PFIC. Investors do not more_horizontal

Albireo Pharma, Inc. (NASDAQ:ALBO ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Hans Vitzthum - Managing Director-Li more_horizontal

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -8.42% and 12.62%, respectively, for the quarter ended March 2022. Do the numbers ho more_horizontal

The lead medicine (Bylvay) is already approved to treat an orphan disease known as progressive familial intrahepatic cholestasis. Leveraging a prudent more_horizontal

Albireo Pharma (ALBO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Albireo Pharma (ALBO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal